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a b s t r a c t
Prasaplai is a medicinal plant mixture that is used in Thailand to treat primary dysmenorrhea, which is
characterized by painful uterine contractility caused by a signiﬁcant increase of prostaglandin release.
Cyclooxygenase (COX) represents a key enzyme in the formation of prostaglandins. Former studies
revealed that extracts of Prasaplai inhibit COX-1 and COX-2. In this study, a comprehensive literature
survey for known constituents of Prasaplai was performed. A multiconformational 3D database was cre-irtual screening ated comprising 683 molecules. Virtual parallel screening using six validated pharmacophore models for
COX inhibitors was performed resulting in a hit list of 166 compounds. 46 Prasaplai components with
already determined COX activity were used for the external validation of this set of COX pharmacophore
models. 57% of these components were classiﬁed correctly by the pharmacophore models. These ﬁnd-
ings conﬁrm that the virtual approach provides a helpful tool (i) to unravel which molecular compounds
might be responsible for the COX-inhibitory activity of Prasaplai and (ii) for the fast identiﬁcation of novel
COX inhibitors.
ntroduction
Virtual screening techniques are very common and widespread
n medicinal chemistry (Ekins et al. 2007b,a; Kirchmair et al. 2008).
he general goal of applying such methods is to ﬁlter large com-
ound databases in silico in order to focus experimental efforts
n those candidates which are most promising for showing the
esired pharmacological effect. Today, the pharmacophore concept
s one of the most widely established methods for virtual screening
Langer et al. 2006; Leach et al. 2010). By deﬁnition, a pharma-
ophore is the ensemble of steric and electronic features that is
ecessary to ensure the optimal supramolecular interactions with
speciﬁc biological target and to trigger or block its biological
esponse (Wermuth et al. 1998). Common pharmacophoric fea-
ures include hydrogen bond donors and acceptors, hydrophobic
nteractions, aromatic ring systems, positively or negatively ioniz-
ble functions, and data on their location in the three-dimensional
3D) space. Moreover, pharmacophore models can be sterically
∗ Corresponding author. Tel.: +43 512 507 5300; fax: +43 512 507 2939.
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restricted by “forbidden” areas, so-called exclusion volumes, and
shapes, of which the latter are usually derived from highly active
ligands. One pharmacophore model usually represents one certain
binding mode to a receptor or an enzyme. If a compound fulﬁls the
requirements of a pharmacophore model, it is more likely to show
biological activity than compounds that do not ﬁt into the model.
Originally, pharmacophore-based virtual screening has been
developed to ﬁnd bioactive synthetic compounds. More recently,
this approach has also shown to be valuable in the ﬁeld of natural
products for the identiﬁcation of bioactive constituents (Rollinger
et al. 2006, 2008). In earlier studies single pharmacophore mod-
els were used for the virtual screening of natural product (NP)
databases (Rollinger et al. 2004, 2005). Technological evolution
enabled upscaling of the virtual screening protocols using parallel
screening (PS) techniques (Rollinger 2009; Rollinger et al. 2009).
In pharmacophore-based PS, single compounds or small databases
are virtually screened against a series of pharmacophore mod-
Open access under CC BY-NC-ND license.els, aiming at the prediction of pharmacological activity proﬁles
of these molecules (Kirchmair et al. 2008; Rollinger 2009). Herein
we present a further application scenario of PS, i.e. the search for
structurally diverse natural compounds with a deﬁned molecular
mode of action.
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Traditional medicine often uses plant mixtures which contain
undreds of compounds from different biosynthetic origin and dif-
erent chemical scaffolds. In this study, we selected Prasaplai, a
hai traditional medicine, as a sample for the application of PS
ecause (i) it is a complexmixture of NPs, (ii) it is used in traditional
edicine to treat inﬂammatory processes (List of Herbal Medicinal
roducts A.D. 2006), and (iii) its anti-inﬂammatory activity has
lready been conﬁrmed. The hexane extract (25gml−1) inhibited
oth cyclooxygenase (COX)-1 and COX-2 up to 64.43 and 84.50%,
espectively (Nualkaew et al. 2005) suggesting that Prasaplai acts
t least partially via the inhibition of COX enzymes.
Prasaplai is composed of twelve ingredients: ten crude plant
rugs (the roots of Acorus calamus L., the bulbs of Allium sativum L.,
he pericarps of Citrus hystrixDC., the rhizomes of Curcuma zedoaria
oscoe, the bulbs of Eleutherine americanaMerr, the seeds ofNigella
ativa L., the fruits of Piper chaba Hunt, the fruits of Piper nigrum L.,
he rhizomes of Zingiber cassumunar Roxb., and the rhizomes of
ingiber ofﬁcinale Roscoe) and two pure compounds (sodium chlo-
ide and camphor). The main component of Prasaplai is Zingiber
assumunar rhizome; itmakesup to50% (w/w)of themixture. Cam-
hormakes up to 0.6% (w/w)while the other components are equal
n weight. Prasaplai is widely used by Thai traditional doctors for
elieving primary dysmenorrhea and adjusting the cycle of men-
truation (List of Herbal Medicinal Products A.D. 2006; Nualkaew
t al. 2004).
The correlationbetweengynecological disorders and the release
f inﬂammatorymediatorswas reviewed recently (Hayes and Rock
002; Connolly 2003). Primary dysmenorrhea is characterized by
ainful uterine contractility caused by a signiﬁcant increase of
rostaglandin release compared with normal menstruation. Since
OX-1 and COX-2 represent key enzymes in the formation of
rostaglandins, inhibitors of COX are effective therapeutics and the
reatment of ﬁrst choice.
COX-1 and COX-2 are ideal model targets for a case study since
-ray crystal structures with bound inhibitors, a large number of
nown active ligands, and datasets for theoretical model valida-
ion are available. In our study, a set of ﬁve structure-based models
nd one ligand-based pharmacophore model for COX inhibitors
ere applied to the constituents of Prasaplai in order to (i) unravel
hich compounds of Prasaplai might be responsible for the COX-
nhibitory activity and (ii) to validate our pharmacophore models
sing published knowledge about constituents of this herbal rem-
dy.
aterials and methods
eneral experimental procedures
Molecular modeling studies were performed on an Intel Pen-
ium Core 2 Duo 6400 equipped with 1GB RAM running Linux
edora Core 6. PS calculations were carried out on an Intel Cen-
rino Core 2 Duo T7500 with 2GB RAM running Windows XP. For
harmacophore model generation and validation and PS experi-
ents the softwareprograms LigandScout 1.03 (Inte:LigandGmbH,
ienna, Austria, 2006), Catalyst 4.11 (Accelrys Software Inc., San
iego, USA, 2005), andDiscovery Studio 2.1 (Accelrys Software Inc.,
an Diego, USA, 2007) were used.
harmacophore modelingPharmacophore models may be obtained either via the
tructure-based or via the ligand-based approach. Structure-based
harmacophore model generation uses 3D structural informa-
ion on the target protein, which is usually obtained from X-ray
rystallography. Protein structures in complex with ligands aredicine 18 (2011) 119–133
publicly available via the Protein Data Bank (PDB) (Berman et al.
2003). Possible chemical interactions between the ligand(s) and
the macromolecule are analyzed, and pharmacophore features
are placed where interactions are observed. For the ligand-based
approach, only information on known biological activity of ligands
is required. Analgorithmdeﬁnes commonchemical features of a set
of bioactive molecules (Schuster and Wolber 2010). For this study,
both approaches were applied. All generated models were theo-
retically evaluated if they found clinically used COX inhibitors and
excluded inactive compounds from the hit list. The best six mod-
els were used for further experiments. A more detailed description
of the pharmacophore model generation and validation and the
PS procedure is provided in part I of this study (Schuster et al.
2010).
NPs database generation
An extensive literature survey was performed in order to col-
lect compounds of the different plants contained in the Prasaplai
mixture. These compounds were stored as 3D structure models in
a database, the so-called Prasaplai database. When stereochem-
istry was not completely speciﬁed, all possible stereoisomers were
built and stored. Since it is not clear, which 3D conformations the
molecules would adopt in the interaction with the target protein,
structures were handled as collections of low-energy 3D conform-
ers.
Parallel virtual screening
The structures in the Prasaplai database were virtually screened
against thepharmacophoremodel set. A compoundwas considered
to be a hit only if all functions of at least one pharmacophore model
were mapped.
Results and discussion
Generation and validation of COX inhibitors pharmacophore
models
Several PDB complexes were used as templates for exhaustive
pharmacophore model generation. Suitable validation processes
were applied to the models to select diverse ones with high
enrichment factors and high restrictivity. This approach led to a
ﬁnal collection of ﬁve structure-based pharmacophore models of
COX enzymes, which were built based upon atomic coordinates
published in PDB entries representing protein/ligand complexes
(Table 1). Since this structure-based model set was not able to
recognize actives of diverse chemical structures, a ligand-based
pharmacophore model was developed that was able to identify
other scaffolds as well. This model was generated by aligning the
bioactive conformations of (S)-ﬂurbiprofen and SC-558 (Schuster
et al. 2010).
Generation and PS of the Prasaplai database
A comprehensive literature survey for known components of
Prasaplai was performed. 3D structures of these compounds were
collected resulting in a molecular library containing a total num-
ber of 683 NPs. The Prasaplai database was subjected to a PS
using the ﬁve structure-based and the ligand-based COX phar-
macophore models. This process resulted in a virtual hit list
containing 166 potential COX inhibitors. Fig. 1 shows the num-
bers of known components of the different plant ingredients of
Prasaplai and the numbers of virtual hits (VH) retrieved from the
PS.
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Table 1
COX Inhibitor Pharmacophore Models used for PS of Prasaplai Components.
3D charta
Name 1cqe-1 1pge-2-s 2ayl-1
PDB entry 1cqe (Picot et al. 1994) 1pge (Loll et al. 1996) 2ayl (Gupta et al. 2006)
Complex COX-1/ﬂurbiprofen COX-1/iodosuprofen COX-1/ﬂurbiprofen
3D charta
Name 4cox-2 6cox-1-s Ligand-based model
PDB entry 4cox (Kurumbail et al. 1996) 6cox (Kurumbail et al. 1996) –
Complex COX-2/indometacin COX-2/S-558 –
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pa 3D chart of pharmacophore model with underlying COX ligand(s). Exclusion vo
epicted to show the steric constraints of the model.
ompound evaluation procedure
The obtained VH were critically analyzed according to their
OX-inhibitory activity that is already evident from literature. For
5 VH literature data about their COX-inhibitory activity were
vailable (Table 2). These compounds are ingredients from ﬁve
f the ten plants Prasaplai is composed of, i.e. Acorus calamus,
igella sativa, Piper nigrum, Zingiber cassumunar and Zingiber ofﬁc-
nale. Consequently, the pharmacophore model set was validated
sing compounds of these ﬁve plants. All known constituents (VH
s well as non-VH, i.e. structures that were not recognized by any
f the six pharmacophore models) of these plants were evalu-
ted on available COX-inhibitory activity. Only those structures
ere considered for the validation process and are described in
etail in this study for which published data about the inhibition
f COX enzymes are available. The relevant non-VH are shown in
able 3.
ig. 1. Number of VH obtained from PS (grey columns) vs. number of known com-
onents of the plants Prasaplai is composed of (white columns).s are omitted for better transparency. Instead, the surface of the binding pocket is
For the validation of the pharmacophore models there was not
differentiated between COX-1 and COX-2 inhibition since the phar-
macophore models are not selective for one isoform. According
to their inhibition values for COX-1 and/or COX-2, the respective
compounds were grouped into three categories: compounds with
IC50 values below 25.0M, between 25.0 and 150.0M, and above
150.0M were considered as highly active, moderately active, and
inactive, respectively. Highly or moderately active VH as well as
inactive non-VH were assumed to be predicted correctly by the
pharmacophore model set; inactive VH as well as highly or mod-
erately active non-VH were assumed to be predicted incorrectly
(Fig. 2). The correctnessof thevirtual predictionwasdetermined for
eachof theseﬁveplants (Table4). Fig. 3 shows thegeneralworkﬂow
performed in this study.
Zingiber cassumunar
Five VH of Zingiber cassumunar have already been evaluated on
their COX-2 inhibitory activity (Table 2). Four compounds showed
IC50 values on COX-2 of 2.71–20.68M. Only one compound was
inactive. Therefore, 80% of the VH were predicted correctly.
For ﬁve non-VH published data about their ability to
inhibit COX were available (Table 3). Limonene, (E)-4-(3,4-
dimethoxyphenyl)but-3-en-1-ol andvanillin showed tobe inactive
on COX-1 and/or COX-2. There are many publications available
describing the suppressive effect of curcumin on the expression
of COX-2 leading to a decreased enzyme activity (Surh and Kundu
2007). However, the information regarding direct inhibition of COX
is inconsistent, showing a range of IC50 from 15.9 to over 100M.
Basedon these data curcuminwas considered asmoderately active.
Except for curcumin, all known actives were found by
the pharmacophore models. These compounds are even highly
active COX inhibitors. The inactives were not recognized, thus
predicted correctly, except for one compound, i.e. (E)-4-(3,4-
dimethoxyphenyl)but-3-en-1-yl acetate.
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Table 2
VH with published COX-inhibitory activities.
Compound Prasaplai plant origin COX-1 inhibitory activity COX-2 inhibitory activity Structure
Palmitic acid Acorus calamus, Nigella
sativa
No inhibition (390M) (Henry et
al. 2002)
No inhibition (390M) (Henry et
al. 2002)
Asaraldehyde Acorus calamus 3.32% (510M) (Momin et al.
2003)
52.69% (510M) (Momin et al.
2003)
-Asarone Acorus calamus 46.15% (480M) (Momin et al.
2003)
64.39% (480M) (Momin et al.
2003)
Myristic acid Nigella sativa No inhibition (438M) (Henry et
al. 2002)
No inhibition (438M) (Henry et
al. 2002)
Pentadecanoic acid Nigella sativa No inhibition (413M) (Henry et
al. 2002)
No inhibition (413M) (Henry et
al. 2002)
-Linolenic acid Nigella sativa, Zingiber
ofﬁcinale
∼93% (359M) (Henry et al. 2002),
IC50 = 52M (Jager et al. 2008)
∼96% (359M) (Henry et al. 2002),
IC50 = 12M (Jager et al. 2008)
Palmitoleic acid Nigella sativa ∼11% (393M) (Henry et al. 2002) No inhibition (393M) (Henry et
al. 2002)
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Linoleic acid Nigella sativa ∼87% (357M) (Henry et al. 2002),
IC50 = 85M (Jager et al. 2008),
IC50 = 52.2M (Su et al. 2002b)
∼94% (357M) (Henry et al. 2002),
IC50 = 0.6M (Jager et al. 2008),
IC50 = 1.9M (Su et al. 2002b)
Oleic acid Nigella sativa 25% (354M) (Henry et al. 2002),
45.32% (354M) (Momin et al.
2003), IC50 = 85.3M (Su et al.
2002b)
Little or no activity (354M)
(Henry et al. 2002), 68.41%
(354M) (Momin et al. 2003),
IC50 = 0.7M (Su et al. 2002b)
Stearic acid Nigella sativa No inhibition (352M) (Henry et
al. 2002; Su et al. 2002b)
No inhibition (352M) (Henry et
al. 2002; Su et al. 2002b)
Erucic acid Nigella sativa No inhibition (295M) (Henry et
al. 2002)
No inhibition (295M) (Henry et
al. 2002)
Eugenol Nigella sativa, Piper
nigrum
nda IC50 = 129M (Huss et al. 2002)
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Table 2 (Continued)
Compound Prasaplai plant origin COX-1 inhibitory activity COX-2 inhibitory activity Structure
Nonanoic acid Piper nigrum 29% (632M) (Henry et al. 2002) Little or no activity (632M)
(Henry et al. 2002)
Octanoic acid Piper nigrum 12% (693M) (Henry et al. 2002) No inhibition (693M) (Henry et
al. 2002)
Methyleugenol Piper nigrum 27.23% (100M) (Yano et al. 2006) 42.64% (100M) (Yano et al. 2006)
(E)-4-(3,4-Dimethoxy-phenyl)but-
3-en-1-yl acetate
Zingiber cassumunar nd IC50 >50M (Han et al. 2005)
4-(2,4,5-Trimethoxy-phenyl)but-
1,3-diene
Zingiber cassumunar nd IC50 =14.97M (Han et al. 2005)
Trans-3-(3,4-dimethoxy-phenyl)-
4-[(E)-3′ ,4′-dimethoxy-
styryl]cyclohex-1-ene
Zingiber cassumunar nd IC50 =2.71M (Han et al. 2005)
4-(3,4-Dimethoxy-phenyl)
but-1,3-diene
Zingiber cassumunar nd IC50 =20.68M (Han et al. 2005)
(±)-Trans-3-(4-hydroxy-3-
methoxy-phenyl)-4-[(E)-3,4-
dimethoxy-styryl]cyclo-hex-1-
ene
Zingiber cassumunar nd IC50 =3.64M (Han et al. 2005)
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[6]-Shogaol Zingiber ofﬁcinale nd IC50 =2.1M (Tjendraputra et al.
2001)
[8]-Gingerdiol Zingiber ofﬁcinale nd IC50 =12.5M (Tjendraputra et al.
2001)
[6]-Paradol Zingiber ofﬁcinale nd IC50 =24.5M (Tjendraputra et al.
2001)
[8]-Gingerol Zingiber ofﬁcinale nd IC50 =10.0M (Tjendraputra et al.
2001)
[8]-Shogaol Zingiber ofﬁcinale nd IC50 =7.2M (Tjendraputra et al.
2001)
a nd, not determined.
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Table 3
Non-VH with published COX-inhibitory activities.
Compound Prasaplai plant origin COX-1 inhibitory activity COX-2 inhibitory activity Structure
Linalool Acorus calamus, Nigella sativa,
Piper nigrum, Zingiber ofﬁcinale
Signiﬁcant reduction of COX-2 expression and PGE2 formation only in
the highest concentration (1000M) (Peana et al. 2006)
Limonene Acorus calamus, Nigella sativa,
Piper nigrum, Zingiber ofﬁcinale,
Zingiber cassumunar
IC50 > 100M (Gerhaeuser et al.
2003b)
nda
Thymoquinone Nigella sativa IC50 = 2.6M (Marsik et al. 2005) IC50 = 0.3M (Marsik et al. 2005)
Thymohydroquinone Nigella sativa IC50 = 0.6M (Marsik et al. 2005) IC50 = 0.1M (Marsik et al. 2005)
Dithymoquinone Nigella sativa IC50 > 100M (Marsik et al. 2005) IC50 = 0.9M (Marsik et al. 2005)
Thymol Nigella sativa IC50 = 0.2M (Marsik et al. 2005) IC50 = 1.0M (Marsik et al. 2005)
Piperine Piper nigrum 33.4% inhibition of PG biosynthesis at 37M (Wagner et al. 1986)
B.W
altenberger
et
al./Phytom
edicine
18 (2011) 119–133
127
Nonanal Piper nigrum Reduction of arachidonic acid metabolites by 50% at ∼0.25M (Sakuma et al. 1997)
Trans-2-nonenal Piper nigrum Reduction of arachidonic acid metabolites by 50% at ∼0.25M (Sakuma et al. 1997)
Safrole Piper nigrum IC50 = 225M (Dewhirst 1980)
Spathulenol Piper nigrum 15% (454M) (Jayaprakasam et al.
2007)
54% (454M) (Jayaprakasam et al.
2007)
Pellitorine Piper nigrum IC50 > 100M (Stohr et al. 1999)
31% inhibition of COX (224M) (Muller-Jakic et al. 1994)
Ledol Piper nigrum No inhibition of PG biosynthesis (37M) (Wagner et al. 1986)
(E)-4-(3,4-Dimethoxy-
phenyl)but-3-en-1-ol
Zingiber cassumunar nd IC50 >50M (Han et al. 2005)
Vanillin Zingiber cassumunar IC50 > 50M (Su et al. 2002a) IC50 > 50M (Su et al. 2002a)
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Table 3 (Continued)
Compound Prasaplai plant origin COX-1 inhibitory activity COX-2 inhibitory activity Structure
Vanillic acid Zingiber cassumunar No inhibition (100M)
(Gerhaeuser et al. 2003a)
nd
Curcumin Zingiber cassumunar IC50 = 18.8M (Gafner et al. 2004),
IC50 = 50M (Handler et al. 2007),
IC50 > 100M (Gerhaeuser et al.
2003b)
IC50 = 15.9M (Gafner et al. 2004),
IC50 > 100M (Handler et al. 2007)
-Sitosterol Zingiber ofﬁcinale No inhibition (241M) (Zhang et
al. 2004)
11% (241M) (Zhang et al. 2004),
IC50 > 241M (Carcache-Blanco et
al. 2006)
6-Hydroxystigmast-4-en-
3-one
Zingiber ofﬁcinale nd IC50 >233M (Carcache-Blanco et
al. 2006)
1,8-Cineole Zingiber ofﬁcinale IC50 > 500M (Dewhirst 1980)
Ascorbic acid Zingiber ofﬁcinale IC50 > 100M (Gerhaeuser et al.
2003b)
IC50 = 3.70M (Fiebich et al. 2003)
a nd, not determined.
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pFig. 2. Decision tree for validingiber ofﬁcinale
Six VH of Zingiber ofﬁcinale have already been tested for their
OX-inhibitory activity (Table 2). [6]-Shogaol, [8]-gingerdiol, [6]-
aradol, [8]-gingerol, and [8]-shogaol showed IC50 values for COX-
Table 4
Determination of correctness of virtual prediction.f pharmacophore model set.2 below 25.0M. Due to its high inhibitory activity especially on
COX-2, -linolenic acid was also considered to be highly active.
For six non-VH data on the inhibition of COX-1 and/or COX-
2 were found (Table 3). According to biological tests, linalool,
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Table 4 (Continued )
aThreshold: active, IC50 ≤150.0M; inactive, IC50 > 150.0M.
bGrey, correct prediction, active VH, inactive non-VH; hatched, false prediction, inactive VH, active non-VH.
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mcCorrectness of prediction referring to one plant. N
structures×100. Example Acorus calamus: three ina
predicted correctly; 40% correct prediction.
imonene, -sitosterol, 6-hydroxystigmast-4-en-3-one, and 1,8-
ineole were classiﬁed as inactive. Ascorbic acid proofed to be
nactive on COX-1 and active on COX-2. According to a third pub-
ication ascorbic acid induces the formation and the release of
OX-catalyzed arachidonic acid metabolites via the activation of
hospholipase A2 (Steinhour et al., 2008). Based on these incon-
istent literate data ascorbic acid was considered as moderately
ctive.
Except for ascorbic acid, all known actives of Zingiber ofﬁci-
ale were predicted correctly (they are even highly active), and
ll known inactives were not recognized by the pharmacophore
odels. This rate of 92% correct prediction is notably high.
igella sativa
For ten VH of Nigella sativa data on their ability to inhibit
OX were available (Table 2). According to their high inhibition
escribed in literature, especially of COX-2, -linolenic acid and
inoleic acid were considered as highly active. Palmitoleic acid,
yristic acid, pentadecanoic acid, palmitic acid, stearic acid, andr of correctly predicted structures/total number of
H, two inactive non-VH; two out of ﬁve structures
erucic acid showed little or no inhibitory activity on COX-1 and
COX-2 and thus were considered as inactive. The available lit-
erature data for oleic acid were inconsistent. Therefore, it was
considered as moderately active. Eugenol has been tested to be
moderately active on COX-2.
The two highly active VH -linolenic acid and linoleic acid
belong to the class of oligo-unsaturated fatty acids. Although
this substance class was not part of either model generation
molecules or model reﬁnement data sets, it was correctly iden-
tiﬁed by the pharmacophore models. This proofs that the model
set can successfully perform the task of scaffold hopping. The
other virtually predicted fatty acids have been determined to be
inactive or have only weak inhibitory activity. Obviously, the phar-
macophore models could not differentiate between these active
and inactive compounds due to their high similarity. Basically,
the substance class comprising active compounds was identi-
ﬁed.
For six non-VH literature data about their COX-inhibitory activ-
ity were found (Table 3). Limonene and linalool have already been
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Basically, the compounds with known activity on COX were
often predicted correctly by the pharmacophore models (Fig. 4,
VH; Fig. 5, non-VH). In the case of Acorus calamus, 40% of the com-
pounds with known activity on COX were predicted correctly, i.e.Fig. 3. General workﬂow of the virtual PS approach performed in this study.
iscussed above. The IC50 values of thymoquinone, thymohydro-
uinone and thymol were determined to be 0.2–2.6M for COX-1
nd 0.1–1.0M for COX-2. Also dithymoquinone showed an IC50
alue for COX-2 of <1.0M.Only its IC50 value for COX-1was deter-
ined to be >100M. The fact that these highly active compounds
ere not recognized by the COX pharmacophore model set may be
ue to different reasons. Our hypothesis is that the structure-based
odels recognize mainly fatty acids, and since these hydroquinone
erivatives belong to a totally different structure class, they were
ot found. For the ligand-based pharmacophoremodel an aromatic
ing is mandatory which thymoquinone and dithymoquinone do
ot comprise. Thymohydroquinone and thymol are too small to
t into the model which results in the missing of one hydropho-
ic feature when mapping the structures into the pharmacophore
odel.
iper nigrum
COX inhibition data were found for four VH of Piper nigrum
Table 2). Eugenol and methyleugenol showed to be moderately
ctive. Nonanoic acid and octanoic acidwere considered to be inac-
ive. For nine non-VH, COX-inhibitory data were available in the
iterature (Table 3). Linalool, limonene, safrole, spathulenol, pel-
itorine, and ledol were described to show no or only weak COX
nhibition. Thus they were considered as inactive. Piperine showed
o be moderately active. Nonanal and trans-2-nonenal were con-
idered as highly active.
In summary, three of those nine non-VH showed inhibitory
ctivity on COX enzymes. We suggest that the structure-based
harmacophore models are very selective and thus do not rec-
gnize these substance classes. In the case of the ligand-based
harmacophore model piperine misses one hydrophobic feature.
he problem of nonanal and trans-2-nonenal is that they do not
eature an aromatic ring. If the aromatic ring in the ligand-based
harmacophore model was exchanged by a hydrophobic feature,
hese two structures were identiﬁed as hits. However, without the
romatic ring the model would be very unselective and PS of the
rasaplai database would retrieve a hit list comprising many false
ositive VH.dicine 18 (2011) 119–133 131
Acorus calamus
For three VH of Acorus calamus literature data about their
COX-inhibitory activity were available (Table 2). Palmitic acid, -
asarone, and asaraldehydewere considered as inactive due to no or
weak inhibition of COX-1 as well as COX-2. Only two non-VH have
already been determined on their COX-inhibitory activity: linalool
and limonene did not show signiﬁcant inhibitory activity on COX
(Table 3).
Allium sativum, Curcuma zedoaria
58 structures from Allium sativum were virtually screened using
thepharmacophoremodel set. This approach resulted inonevirtual
hit (S-allylmercaptocysteine). Literature survey for COX inhibition
data for this substance did not retrieve any information. The virtual
screening of the 104 structures from Curcuma zedoaria resulted in a
hit list comprising ﬁve structures. Also for these ﬁve compounds no
literature data about their COX-inhibitory activity were available.
COX-inhibitory effects of plant extracts have been reported (Sendl
et al. 1992; Ali et al. 1993; Ali 1995; Tohda et al. 2006). However,
since there was no information available about the correctness of
the prediction of those VH, compounds of these plants were not
used for the validation of the pharmacophore models.
Citrus hystrix, Eleutherine americana, Piper chaba
The PS of the 37 structures from Citrus hystrix, the 14 from
Eleutherine americanaand the18 fromPiper chabawith the sixphar-
macophoremodels resulted in hit lists comprising four, eleven, and
twelve structures, respectively. Since literature data on COX inhi-
bition for any of those hits were not available, compounds of these
plants were not included in the validation process.
Camphor, sodium chloride, artefacts
Camphor and sodium chloride are the two pure compounds
in the Prasaplai mixture. Therefore camphor was also added to
the molecule library that was virtually screened with the phar-
macophore models, as well as the three artefacts that originate
during storage of Prasaplai. These fatty acid esters arise from the
interaction of compounds of Nigella sativa and Zingiber cassumunar
(Nualkaew et al. 2004). Camphor was not recognized by the phar-
macophore models, the three artefacts were found. However, their
COX-inhibitory activity has not been determined yet.
Summary of pharmacophore models validationFig. 4. Numbers of VH included in pharmacophore models validation. Threshold:
highly active, IC50 < 25.0M (dark grey); moderately active, IC50 = 25.0–150.0M
(light grey); inactive, IC50 > 150.0M (white).
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Cig. 5. Numbers of non-VH included in pharmacophore models valida-
ion. Threshold: highly active, IC50 < 25.0M (dark grey); moderately active,
C50 = 25.0–150.0M (light grey); inactive, IC50 > 150.0M (white).
wo inactives out of ﬁve compounds with experimentally deter-
ined COX-inhibitory activity. For the compounds ofNigella sativa,
iper nigrum, and Zingiber cassumunarwith known activity on COX-
8, 62, and 80% correct prediction was obtained, respectively. For
he compounds of Zingiber ofﬁcinale the highest rate of correct pre-
iction was achieved: eleven out of twelve components, i.e. 92%.
nly one active non-VH, ascorbic acid, was not recognized by the
harmacophore model set, thus predicted incorrectly.
In total, fromthe25VHwithknownactivityonCOX, elevenwere
eported to be highly active, three moderately active, and eleven
nactive. This gives a rate of correct prediction of 56%. Further, out
f the 21 non-VH already determined for their COX activity, six
re highly active, three are moderately active and twelve non-VH
re inactive, resulting in 57% of correct prediction. Thus, also the
ombinationof theseVHandnon-VHprovides a total rate of correct
rediction of 57%, i.e. 26 out of 46 compounds.
iscussion
In general, random screening or high-throughput screening of
nbiased sets of compounds results in estimated average hit rates
f 0.05–0.2%. With virtual screening techniques average hit rates
f 5–25% are commonly gained (Oprea 2004). When interpreting
hese values it has to be considered that the hit rates are highly
ependent on the target and the quality of the pharmacophore
odels, which again are closely related to the available structural
nformation used as starting point for model generation.
On average the virtual prediction of Prasaplai components was
atisfactory. Although 0% of the VHofAcorus calamuswas predicted
orrectly (noneof the threeVHwas considered tobeactive), rates of
orrect prediction of 40, 50 and even 80% could be achieved by the
H of Nigella sativa, Piper nigrum, and Zingiber cassumunar, respec-
ively. The highest rate was obtained by the VH of Zingiber ofﬁcinale
100%). The resulting average rate of correct prediction of 56% is
omparable to published virtual prediction values in the ﬁeld of
harmaceutical chemistry (Doman et al. 2002).
The evaluation of the performed computational approach
nderlying this study is inﬂuenced by different factors. In many
ases negative results from biological testing are not published.
e suggest that this is the reason we found only a small num-
er of inactive substances in literature (23 vs. 23 actives). Another
roblem represents the reliability of literature data. Even if the data
re correct, the authors of the publications used different test sys-
ems, which results in the problem that inhibition values cannot be
irectly compared. Even literature data regarding one compound
re often inconsistent.
In general, one reason for not ﬁnding actives might be the fact
hat a pharmacophore model only represents one binding mode.
onsequently, the inhibitory activity of a compound might be duedicine 18 (2011) 119–133
to another binding mode which is not covered by the pharma-
cophore model set.
However, by the application of the Prasaplai components to PS
with a set of COX pharmacophore models, molecular compounds
were identiﬁed that are at least in part responsible for the COX-
inhibitory activity of the Thai mixture. Furthermore, the results of
the pharmacophore models validation with Prasaplai components
conﬁrm that – in comparison to a random screening approach – the
virtual approach is able to increase the chance to ﬁnd actives.
Conclusion
Computational approaches are effective strategies in drug dis-
covery. They have the potential to decrease cost and time of
drug development. In this study, the applicability and efﬁciency of
pharmacophore-based PS was shown when searching for bioactive
NPs. In this application scenario, active compounds were success-
fully identiﬁed from a structurally diverse mixture. In total, 57% of
the compounds in the validation set were predicted correctly by
the COX pharmacophore models. Thus, the pharmacophore-based
virtual PS revealed as a powerful tool to identify COX inhibitors
from a complex mixture of NPs. We suggest that this approach can
be applied to several kinds of plants and plant mixtures and is not
limited to COX enzymes but can also be used for other targets.
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